Global Nucleic Acid Amplification Market – Industry Trends and Forecast to 2030

 Análisis y tamaño del mercado de amplificación de ácidos nucleicos

Según el informe de octubre de 2021 de la Organización Mundial de la Salud, la tuberculosis está presente en todos los países y grupos de edad, y aproximadamente 10 millones de personas enfermaron de tuberculosis (TB) en todo el mundo en 2020, y ocho países representaron dos tercios del total de casos de TB, con India a la cabeza, seguida de China, Indonesia, Filipinas, Pakistán, Nigeria, Bangladesh y Sudáfrica. Además, según la hoja informativa Estadísticas mundiales sobre el VIH y el sida 2021 del Programa Conjunto de las Naciones Unidas sobre el VIH/SIDA (ONUSIDA), 37,7 millones de personas en todo el mundo vivían con el VIH en 2020. Como resultado, se espera que la creciente prevalencia de enfermedades infecciosas impulse el crecimiento del mercado.

Data Bridge Market Research analiza que se espera que el mercado de amplificación de ácidos nucleicos, que es de USD 3.27 mil millones en 2022, alcance los USD 6.66 mil millones para 2030, a una CAGR del 9.3% durante el período de pronóstico de 2023 a 2030. Además de los conocimientos sobre escenarios de mercado como valor de mercado, tasa de crecimiento, segmentación, cobertura geográfica y actores principales, los informes de mercado seleccionados por Data Bridge Market Research también incluyen análisis de expertos en profundidad, epidemiología de pacientes, análisis de canalización, análisis de precios y marco regulatorio.

Alcance y segmentación del mercado de amplificación de ácidos nucleicos  

Definición de mercado

Una prueba de amplificación de ácidos nucleicos, o NAAT, es un tipo de prueba de diagnóstico viral para el virus que causa COVID-19, SARS-CoV-2. Las NAAT reconocen material genético (ácidos nucleicos). Las NAAT para SARS-CoV-2 identifican específicamente las secuencias de ARN (ácido ribonucleico) que componen el material genético del virus. Las NAAT para SARS-CoV-2 examinan muestras del tracto respiratorio superior o inferior. El tipo de muestra recolectada durante la prueba de SARS-CoV-2 está determinado por la prueba que se realiza y las instrucciones del fabricante. Recolección y manejo de muestras clínicas para pruebas de COVID-19 por parte de los CDC

Dinámica del mercado de amplificación de ácidos nucleicos

Conductores

• Creciente demanda de productos INAAT

Para satisfacer la creciente demanda de ofertas de INAAT, los actores clave están ampliando su cartera de productos mediante la introducción de reactivos avanzados para los productos INAAT más recientes. Por ejemplo, Thermo Fisher Scientific, Inc. lanzó su Invitrogen Super Script IV RT-LAMP Master Mix para la detección de varios patógenos virales en marzo de 2022. Estos lanzamientos de productos impulsan el crecimiento del mercado al ampliar la utilidad de las técnicas INAAT en una amplia gama de aplicaciones.

• Aumento de casos de cáncer

Según la Sociedad Estadounidense del Cáncer, en 2020 se diagnosticarán en Estados Unidos 1.806.590 nuevos casos de cáncer y 606.520 personas morirán a causa de esta enfermedad. La creciente carga de cáncer aumenta la demanda de pruebas diagnósticas como la NAAT. Además, la Hepatitis Foundation estima que hasta 2,2 millones de personas estarán infectadas crónicamente con hepatitis B en 2021, pero solo el 25% de los infectados serán diagnosticados. Como resultado de la creciente necesidad de mejores pruebas diagnósticas en las regiones, los principales actores y el gobierno se están centrando en tecnologías emergentes con mayor eficacia, como las pruebas de amplificación de ácidos nucleicos.

Oportunidades

• Desarrollos tecnológicos

A few of the country's key market players are developing advanced diagnostics kits to compete with existing products, while others are acquiring and partnering with other market players. For instance, in March 2022, Thermo Fisher Scientific introduced two novel reverse transcription loop-mediated isothermal amplification (RT-LAMP)-based solutions to support ongoing viral infection research and surveillance, including SARS-CoV-2. While PCR remains the gold standard for diagnostic, lab-based testing, isothermal RT-LAMP nucleic-acid based amplification provides a quick and cost-effective option for identifying viral infections. Such developments are bolstering the region's market growth.

Restraints/Challenges

• High cost of tonometer devices

High cost of nucleic acid amplification and the low adoption rate in emerging and underdeveloped countries will obstruct the market's growth rate.

This nucleic acid amplification market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the nucleic acid amplification market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Nucleic Acid Amplification Market

COVID-19 has boosted market growth by increasing demand for rapid and accurate testing alternatives for detecting the SARS-CoV-2 virus. Several key players have developed new INAAT-based COVID-19 testing products and obtained emergency use approvals from the US FDA for such products. For instance, Grifols Diagnostic Solutions Inc.'s Procleix SARS-CoV-2 assay and Lucira Health, Inc.'s Lucira CHECK-IT COVID-19 test kit, are commercially available products in this domain. Such COVID-19-fueled strategic initiatives are likely to provide a significant boost to market growth in the near future.

Recent Developments

• In 2022, The US Food and Drug Administration granted Emergency Use Authorization to Abbott's ID Now COVID-19 2.0 quick point-of-care test. The test is performed using the company's ID Now technology, which employs isothermal nucleic acid amplification to detect infectious illnesses qualitatively.
• In 2020, Abbott received FDA approval for the emergency use of ID NOW COVID-19, a nucleic acid amplification test (NAAT), an isothermal, rapid system for qualitatively detection of COVID-19.

Global Nucleic Acid Amplification Market Scope

The nucleic acid amplification market is segmented on the basis of application and technique. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Application

• Infectious Diseases
• Cancer
• Personalized Medicine
• Genetic

Technique

• Target Amplification
• Probe Amplification
• Signal Amplification

Nucleic Acid Amplification Market Regional Analysis/Insights

The nucleic acid amplification market is analyzed and market size insights and trends are provided by country, application and technique as referenced above.

The countries covered in the nucleic acid amplification market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The nucleic acid amplification market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for nucleic acid amplification market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the nucleic acid amplification market. The data is available for historic period 2011-2021.

Competitive Landscape and Nucleic Acid Amplification Market Share Analysis

The nucleic acid amplification market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to nucleic acid amplification market.

Some of the major players operating in the nucleic acid amplification market are:

• Siemens (Germany)
• Hologic, Inc. (U.S.)
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
• Abbott (U.S.)
• BD (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Thermo Fisher Scientific Inc. (U.S.)
• Koninklijke Philips N.V. (Netherlands)
• NeuroLogica Corp. (U.S.)
• Shimadzu Medical (India) pvt. Ltd. (Japan)
• General Electric (U.S.)
• Quest Diagnostics Incorporated (U.S.)
• Sysmex India Pvt. Ltd. (Japan)
• Hitachi, Ltd. (Japan)
• Canon Inc. (Japan)
• FUJIFILM Holdings Corporation (U.K.)

SKU-59350